Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2024-07-22 Report Publication Anno…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Results of the Annual and Extraordinary Meeting held on July 22, 2024
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed under Regulation 4 of the Securities Regulations, specifically mentioning the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, 'Attached hereto is a report on *ea020979201_6k_xtlbioEDGAR3_Bannerless_isa.pdf*'. The document itself is very short (1831 characters) and serves only to announce the attachment of a primary report, which is likely a Form 6-K based on the filename pattern often associated with foreign private issuers reporting to the SEC, but the immediate purpose here is the announcement of publication. According to Rule 2, when a document is short and announces the attachment/publication of another report, it should be classified as a Report Publication Announcement (RPA).
2024-07-22 English
REPORT OF FOREIGN PRIVATE ISSUER
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It announces the results of an Annual and Extraordinary General Meeting held on July 22, 2024, including shareholder approvals of various resolutions such as appointment of auditors, re-election of board members, and approval of an acquisition transaction. The document primarily reports voting results from the shareholder meeting rather than providing the full meeting materials or detailed financial reports. The presence of detailed voting outcomes and shareholder resolutions aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4645 characters, which is sufficient to include detailed voting results rather than just an announcement of a report publication. Therefore, the correct classification is DVA with high confidence.
2024-07-22 English
Immediate Report of Meeting To Be Held On July 22, 2024,PROXY STATEMENT
Director's Dealing Classification · 98% confidence The document text consists of multiple declarations titled "Declaration of Director's Qualification" under Section 224(b) of the Israeli Companies' Law - 1999. These declarations detail the qualifications, experience, and shareholdings of individuals (Alexander Rabinovich, Shlomo Shalev, Doron Turgeman, I21 Klinger) intended to serve as directors for XTL BIOPHARMACEUTICALS Ltd. This content directly relates to the composition, structure, and governance of the company's board of directors and management. This aligns best with the 'Board/Management Information' category (MANG), which covers announcements of changes in the board of directors or senior management, as this document serves to qualify new or continuing directors.
2024-06-12 English
Immediate Report of Meeting To Be Held On July 22, 2024,PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document explicitly states it is a 'PROXY FOR THE ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 22, 2024'. It details proposals for voting, including the appointment of auditors, re-election of directors, and approval of a transaction. This content is characteristic of materials used to solicit shareholder votes for a general meeting, which aligns directly with the definition of a Proxy Solicitation & Information Statement (PSI). While it relates to the AGM, the specific function here is soliciting the proxy vote, making PSI the most precise fit over AGM-R (which is for presentations/materials shared *during* the meeting).
2024-06-12 English
Immediate Report of Meeting To Be Held On July 22, 2024,PROXY STATEMENT
AGM Information Classification · 98% confidence The document is explicitly titled as a 'FORM 6-K' filed with the SEC for the month of June 2024. The content details the announcement of an 'Annual and Extraordinary General Meeting of Shareholders' (the 'Meeting') scheduled for July 22, 2024. It includes the 'Notice and Proxy Statement' (Exhibit 99.1) and forms for proxy cards/voting instruction cards. The core purpose of this filing is to provide the necessary documentation and notice for the upcoming shareholder meeting, which aligns perfectly with the definition of materials shared during an Annual General Meeting (AGM). Although it contains a Proxy Statement (which might suggest PSI), the context is the official filing announcing the AGM and attaching the related materials, making AGM-R the most appropriate primary classification for the overall filing package, especially since the agenda covers standard AGM items like auditor reappointment and director elections. Since the document is a comprehensive filing (Form 6-K) containing the full notice and proxy materials, it is classified as AGM-R rather than just RPA or PSI.
2024-06-12 English
Immediate Report of Meeting To Be Held On July 22, 2024,PROXY STATEMENT
AGM Information Classification · 98% confidence The document explicitly states it is giving 'notice of: convening of meeting' for an 'extraordinary meeting' scheduled for 22/07/2024. It details the agenda items, which include discussing the auditor's report, appointing auditors, and re-electing directors. This structure—a formal notice detailing the date, time, location, and agenda for a shareholder meeting—is characteristic of materials related to an Annual General Meeting (AGM) or an Extraordinary General Meeting (EGM). Since the agenda includes standard AGM items like auditor approval and director elections, and the document is a notice for convening the meeting, the most appropriate classification is AGM-R (AGM Information), as it pertains directly to the meeting itself.
2024-06-12 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.